Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427364 | 1.00 | MGLL (0.40) | MGLLHDAC2HDAC1CACNA1HCCR3 | |
| SCHEMBL12295693 | 0.93 | MGLL (0.39) | MGLLHDAC2HDAC1MMEL1 | |
| SCHEMBL2431699 | 0.89 | MGLL (0.51) | MGLL | |
| SCHEMBL2431708 | 0.89 | MGLL (0.51) | MGLL | |
| SCHEMBL2425964 | 0.87 | MGLL (0.41) | MGLLCACNA1HMMEL1ALDH1A1NPY5R | |
| SCHEMBL12295646 | 0.87 | MGLL (0.41) | MGLLALDH1A1 | |
| SCHEMBL2425006 | 0.85 | MGLL (0.44) | MGLL | |
| SCHEMBL12295692 | 0.84 | MGLL (0.36) | MGLLNPY5R | |
| SCHEMBL2429009 | 0.83 | MGLL (0.39) | MGLLHDAC2HDAC1NPY5R | |
| SCHEMBL2421966 | 0.83 | MGLL (0.39) | MGLLHDAC2HDAC1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | MGLL 246/4885HDAC2 573/4885HDAC1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.